

Act of 1995, no person shall re

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

(Use as many sheets as necessary)

Sheet	1	of	4
-------	---	----	---

Complete if Known

Application Number	10/731,225
Filing Date	December 9, 2003
First Named Inventor	Charles Price Taylor, Jr., et al.
Art Unit	1614
Examiner Name	Not Yet Known
Attorney Docket Number	PC 25677A

[illegible]

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ² *Number ⁴ *Kind Code ⁵ (if known)	MM-DD-YYYY		
mb		EP 0 974 351 A2/A3	01/26/2000	Guglietta, et al	
		WO 00/02546 A2/A3	01/20/2000	Magnus-Miller, et al	
I		WO 00/31020	06/02/2000	Belliotti, et al	
		WO 00/67742 A1	11/16/2000	Magistro	
		WO 00/76958 A2/A3	12/21/2000	Belliotti, et al	
		WO 02/100347 A2/A3	12/19/2002	Gallop, et al	

Examiner
Signature

Michael Lafolco

Date
Considered

17. Apr. 06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Examiner Signature	<i>Michael L. Lister</i>	Date Considered	17. Apr. 02
-----------------------	--------------------------	--------------------	-------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/731,225		
		Filing Date	December 9, 2003		
		First Named Inventor	Charles Price Taylor, Jr., et al.		
		Art Unit	1614		
		Examiner Name	Not Yet Known		
Sheet	3	of	4	Attorney Docket Number	PC 25677A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
mc		AMERINGEN VAN M., et al., "Drugs in Development for Social Anxiety Disorder More to Social Anxiety Than Meets the SSRI", Expert Opinion on Investigational Drugs, (2000), pp. 2215-2231, Vol. 9(10)	
		BELOZERTSEVA I V, et al., "A Pharmacological study of the GABA-ergic mechanisms regulation the depression-like behavior of mice", US National Library of Medicine, (1997) , pp 1024-1031, Vol. 47	
		BRILEY, et al., "Fibromyalgia Syndrome", Overview of Potential Drug Targets, (2003), pp 668-673, Vol. 6	
		DANILIN V P, et al., "Effect of Fenibut on the nocturnal sleep of patients with the alcoholic abstinence syndrome", US National Library of Medicine, (1986), pp 251-254, Vol. 86(2)	
		DAVIDSON J.R.T., "Advances and Emerging Treatments in social Phobia", Journal of clinical Psychiatry, (2001), pp. 4, Vol 62(1)	
		FELTNER, et al., "A Placebo-Controlled Double-Blind Study of Pregabalin Treatment of social Phobia", European Neuropsychopharmacology, (2000), pp. S345, Vol. 10(3)	
		GUYMER E K, et al., "An Approach to Managing Fibromyalgia", Medicine Today, (2002), pp. 58-59, Vol. 3(12)	
		HIDALGO, et al., "Social Anxiety Disorder in Review", International Journal of Neuropsychopharmacology, (2001), pp 279-289, Vol. 4(3)	
		KUBOTA, et al, "Pregabalin Enhances Nonrapid Eye Movement Sleep", The Journal of Pharmacology and Experimental Therapeutics, (2001), pp 1095-1105, Vol. 299	
		MARSHALL, et al., "Changes in immune cell counts and interleukin (IL) -1 'beta' production in humans after a somnogenically active growth hormone-releasing hormone(GHRH) administration", Elsevier Science Publishers, (2001), pp 227-234, Vol. 15(3)	

Examiner Signature	<i>Michel Jaffro</i>	Date Considered	17-Apr-06
--------------------	----------------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete If Known			
		Application Number	10/731,225		
		Filing Date	December 9, 2003		
		First Named Inventor	Charles Price Taylor, Jr., et al.		
		Art Unit	1614		
		Examiner Name	Not Yet Known		
Sheet	4	of	4	Attorney Docket Number	PC 25677A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
mb		MELTZER, et al., "Pregabalin Enhances Non-Rapid Eye Movement Sleep AND EEG Slow-Wave Activity in Rats", Society for Neuroscience Abstracts, (2001), pp 2245, Vol. 27(2)	
I		SELAKE I., Pregabalin, Current Opinion in Investigational Drugs, (2001), pp 828-834, Vol. 2(6)	
I		VLASOV N. A., "Effects of Derivatives of GABA on Sleep Disturbances in Neurosi", Bulletin of Experimental biology and Medicine, (1978), pp. 169-171, Vol. 85(2)	


Examiner Signature	<i>Michael Jaffer</i>	Date Considered	17. Apr. 06
--------------------	-----------------------	-----------------	-------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Confirmation No.

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/731,225
Filing Date	December 9, 2003
First Named Inventor	Charles Price Taylor, Jr., et al.
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	PC25677A

Sheet 1 of 2

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
mb I		US- 4,024,175	05/17/1977	G. Satzinger, et al.	
		US- 4,087,544	05/02/1978	G Satzinger, et al.	
		US- 5,563,175	10/08/1996	R. B. Silverman, et al.	
		US- 6,316,638	11/13/2001	J. S. Bryans, et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ³
		Country Code ² -Number ⁴ -Kind Code ⁵ (if known)				
mb I		WO 99/08671	02/25/1999	A. Guglietta, et al.		
		WO 99/61424	12/02/1999	J. S. Bryans, et al.		
		WO 00/15611	03/23/2000	J. S. Bryans, et al.		
		WO 03/063845	08/07/2003	D. J. Dooley, et al.		
		WO 2004/016259	02/26/2004	M. J. Field, et al.		
		WO 2004/016260	02/26/2004	D. C. Blakemore, et al.		

Examiner Signature	<i>Michael Stappeler</i>	Date Considered	17. Apr. 06
--------------------	--------------------------	-----------------	-------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

US 10/731,225 FILED December 9, 2003
Docket No. PC25677A

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/731,225
Filing Date	December 9, 2003
First Named Inventor	Charles Price Taylor, Jr., et al.
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	PC25677A

Sheet	2	of	2
-------	---	----	---

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	<i>Michael Foster</i>	Date Considered	17.12.02
-----------------------	-----------------------	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.